B-type natriuretic peptide (BNP) testing and monitoring in patients with heart failure (HF) in primary and secondary care in the UK

Submission date	Recruitment status No longer recruiting	Prospectively registered		
09/08/2013		[X] Protocol		
Registration date	Overall study status	Statistical analysis plan		
14/08/2013	Completed	[X] Results		
Last Edited 22/01/2019	Condition category Circulatory System	[] Individual participant data		

Plain English summary of protocol

Background and study aims

B-type natriuretic peptide (BNP) is a substance in the blood that is raised in patients with heart failure. There is evidence that measuring BNP regularly over time and adjusting medications to lower BNP levels improves health outcomes in these patients. Currently, it is unknown whether any heart failure patients in the UK receive serial BNP monitoring and, if yes, whether this has changed patient management and improved clinical outcomes. The main aim of this study is to find out whether BNP testing and monitoring improves outcomes for patients with heart failure.

Who can participate?

Patients with heart failure aged 18 and over

What does the study involve?

Patient information is collated from GP practices and hospitals, and linked with hospital record data and death registry data. A small group of patients have BNP measurements recorded. Groups with and without BNP measurements are compared for differences in health outcomes. A health economic analysis is also undertaken to determine whether measuring BNP is cost effective in the NHS.

What are the possible benefits and risks of participating?

There will be no risk to patients because all information will be provided in a format that will not include names, addresses, date of birth, or any other identifiable information.

Where is the study run from? University of Bristol (UK)

When is the study starting and how long is it expected to run for? August 2013 to January 2015

Who is funding the study? National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (UK)

Who is the main contact?
Dr Maria Pufulete
maria.pufulete@bristol.ac.uk

Contact information

Type(s)

Scientific

Contact name

Prof Barney Reeves

Contact details

Clinical Trials and Evaluation Unit School of Clinical Sciences University of Bristol Level 7, Bristol Royal Infirmary Queen's Building Bristol United Kingdom BS2 8HW

-

barney.reeves@bristol.ac.uk

Additional identifiers

Protocol serial number

HTA 11/102/03

Study information

Scientific Title

Effectiveness and cost-effectiveness of serum B-type natriuretic peptide (BNP or NT-BNP) testing and monitoring in patients with heart failure (HF) in primary and secondary care

Study objectives

Compared with symptom-guided therapy (standard care), BNP-guided testing and monitoring reduces mortality and hospital admission in patients with chronic heart failure in the UK and is cost effective to the NHS.

More details can be found at: https://www.journalslibrary.nihr.ac.uk/programmes/hta/1110203 /#/

Ethics approval required

Old ethics approval format

Ethics approval(s)

The cohort will be established by the UK Clinical Practice Research Datalink (CPRD), which holds standing ethical approval for observational studies using anonymised CPRD GOLD data. Our study therefore does not require separate ethical approval from an NHS Research Ethics Committee.

Study design

Longitudinal cohort study

Primary study design

Observational

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Heart failure

Interventions

Exposure: Any BNP measurement (single or multiple).

Comparator: No BNP measurement.

Patient information is collated from GP practices and hospitals, and linked with hospital record data and death registry data. A small group of patients have BNP measurements recorded. Groups with and without BNP measurements are compared for differences in health outcomes. A health economic analysis is also undertaken to determine whether measuring BNP is cost effective in the NHS.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

All-cause mortality within 12 months

Key secondary outcome(s))

- 1. Time from diagnosis of HF (time origin for all time-to-event analyses) to emergency in hospital admission/unscheduled readmission
- 2. Length of hospital stay
- 3. Prescribed medications on discharge
- 4. Time on medication
- 5. Time to change in medication
- 6. Annual rate of outpatient clinic and general practice attendance and associated investigations

Completion date

31/01/2015

Eligibility

Key inclusion criteria

All patients with primary diagnosis of heart failure in CPRD or NHFA, diagnosed between April 2005 and March 2013 (CPRD) and April 2009 and March 2013 (NHFA). HF diagnoses in CPRD will be identified using the Read codes. Code sets will be selected with the help of CPRD researchers and agreed by clinical members of the research team.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

Patients who do not meet the inclusion criteria above

Date of first enrolment

01/08/2013

Date of final enrolment

31/01/2015

Locations

Countries of recruitment

United Kingdom

England

Study participating centre University of Bristol

Bristol United Kingdom BS2 8HW

Sponsor information

Organisation

University Hospitals Bristol NHS Foundation Trust (UK)

ROR

https://ror.org/04nm1cv11

Funder(s)

Funder type

Government

Funder Name

Health Technology Assessment Programme

Alternative Name(s)

NIHR Health Technology Assessment Programme, Health Technology Assessment (HTA), HTA

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient- facing?
Results article	results	01/08 /2017	22/01 /2019	Yes	No
Results article	results	31/07 /2018	22/01 /2019	Yes	No
Results article	results of model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure.	28/12 /2016	22/01 /2019	Yes	No
Results article	results of the healthcare costs of heart failure during the last five years of life.	01/12 /2016	22/01 /2019	Yes	No
Protocol article	protocol	02/05 /2014	22/01 /2019	Yes	No
Participant information	Participant information sheet	11/11	11/11	No	Yes

<u>sheet</u> /2025 /2025